The pharmacokinetics and pharmacodynamics of phytocannabinoids significantly influence their potential to modulate sodium–glucose cotransporter 2 (SGLT2) for T2DM management. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.